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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2016, TaiwanBackground: The aim of this study was to compare the efficacy and adverse effects of various
intratracheal beractant administration positions in preterm newborns with respiratory distress
syndrome.
Methods: This study was performed on preterm newborns with respiratory distress syndrome.
The inclusion criteria were being between 26 weeks and 32 weeks of gestational age, having a
birth weight between 600 g and 1500 g, having received clinical and radiological confirmation
for the diagnosis of respiratory distress syndrome (RDS) within 3 hours of life, having been born
in one of the centers where the study was carried out, and having fractions of inspired oxygen
(FiO2)  0.40 to maintain oxygen saturation by pulse oximeter at 88e96%. Beractant was
administered in four positions to Group I newborns, in two positions to Group II, and in neutral
position to Group III.
Results: Groups I and II consisted of 42 preterm infants in each whereas Group III included 41
preterm infants. No significant differences were detected among the groups with regards to
maternal and neonatal risk factors. Groups were also similar in terms of the following compli-
cations: patent ductus arteriosus (PDA), pneumothorax, intraventricular hemorrhage (IVH),t of Pediatrics, Division of Neonatology, School of Medicine, Inonu University, Turgut Ozal Medical
.com.tr (R. Ozdemir).
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106 A. Karadag et alchronic lung disease (CLD), retinopathy of prematurity (ROP), necrotising enterocolitis (NEC),
death within the first 3 days of life, death within the first 28 days of life, and rehospitalization
within 1 month after discharge. Neither any statistically significant differences among the pa-
rameters related with surfactant administration, nor any significant statistical differences
among the FiO2 levels and the saturation levels before and after the first surfactant adminis-
tration among the groups were determined.
Conclusion: In terms of efficacy and side effects, no important difference was observed be-
tween the recommended four position beractant application, the two position administration,
and the neutral position.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Respiratory distress syndrome (RDS) remains the most
frequent cause of mortality and morbidity in preterm
newborns. However, it is known that administration of
exogenous surfactants improves alveolar oxygenation and
reduces mortality and morbidity rates among preterm
newborns with RDS.1e4 Several types of surfactant prep-
arations, including synthetic preparations, which are
protein-free, and natural preparations, from bovine or
porcine origin, have been used in the treatment of
RDS.5e9
Beractant is a bovine-derived natural surfactant used in
preventing and treating RDS in premature newborns. Sur-
vanta (AbbVie Inc., North Chicago, IL, USA) is the only
beractant preparation administered worldwide. The Food
and Drug Administration (FDA) has approved the adminis-
tration of Survanta for prevention and treatment of RDS in
newborns since 1991.10 The manufacturing company ac-
quired FDA approval for the product by defining the
administration of the beractant preparation as follows: for
a homogenous distribution of Survanta throughout the
lungs, each total dose is divided into four quarter-doses,
also known as aliquots (4 aliquots Z 1 total dose). How-
ever, there are some difficulties concerning the adminis-
tration of the surfactant in four positions. In the
application of certain surfactant preparations, infants are
not obliged to be in position.10 In addition, the fact that
surfactant can be administered in a neutral position has
also established a tendency in neonatologists to apply
surfactant in positions other than the four positions offered
by the manufacturer. In different countries, many neo-
natologists use the beractant either in the two positions or
in the neutral position, despite manufacturer’s in-
structions. Although widespread in practicality, there are
no data concerning the efficacy and diverse effects of the
beractant application apart from those of the four positions
in the early and late periods.
In this randomized controlled multicenter study, our aim
was to compare the efficacy and side effects of beractant
application in the four positions suggested by the manu-
facturer, in two positions, and in the neutral position in the
early and late periods.2. Methods
The following randomized controlled multicenter study was
conducted in four different centers in Turkey. Preterm
newborns were considered eligible for the study when they
met the following inclusion criteria: being between 26
weeks and 32 weeks of gestational age, having a birth
weight between 600 g and 1500 g, having received clinical
and radiological confirmation for the diagnosis of RDS
within 3 hours of life, having been born in one of the cen-
ters where the study was carried out, and having fractions
of inspired oxygen (FiO2)  0.40 to maintain oxygen satu-
ration by pulse oximeter at 88e96%. Preterms with chro-
mosomal defects, asphyxia, congenital heart and lung
diseases, and those who had or needed chest compression
or drug use in the delivery room, along with preterm babies
who were delivered from mothers with membrane rupture
for > 2 weeks were all excluded from the study. The
Institutional Ethics Committee of Inonu University, Malatya,
Turkey approved the initiation of the study, and parental
consent was obtained for all participants.
All newborns in the study were diagnosed with RDS both
clinically and radiologically. Tachypnea (> 60 breaths/
min), retractions, nasal flaring, grunting, the need to
maintain the oxygen saturation at  86% with FiO2  0.40 in
addition to the chest radiograph results with  2 Grade 2
RDS findings confirmed the RDS diagnosis. The classification
of pulmonary X-ray findings for RDS included the following
criteria: Grade 1, slight reticular (slightly granular)
decrease in transparency of the lung with no certain dif-
ference from normal findings; Grade 2, soft decrease in
transparency with an airebronchogram overlapping the
heart; Grade 3, gradual but strong decrease in trans-
parency, as well as a blurry diaphragm and heart; and
Grade 4, practically homogenic lung opacity.11
The patients were randomized into three different
groups according to surfactant administration positions. In
Group I, the surfactant was administered in four positions
whereas it was administered in two positions in Group II,
and in the neutral position in Group III (Figures 1e3). In
Group I, the manufacturer’s suggested positions were fol-
lowed: head and body inclined 5e10 down with the head
turned to the right; head and body inclined 5e10 down
Figure 1 Chest X-rays (A) before and (B) after first surfactant administration in Group 1.
Figure 2 Chest X-rays (A) before and (B) after first surfactant administration in Group 2.
Figure 3 Chest X-rays (A) before and (B) after first surfactant administration in Group 3.
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5e10 up while the head is turned to the right; and head
and body inclined 5e10 up while the head is turned to the
left. The two positions administered in Group II were as
follows: head and body inclined 5e10 up with the head
turned to the right and head and body inclined 5e10 up
with the head turned to the left. Group III patients in the
neutral position were positioned in supine position with
head and feet level and in line and without turning the headsideways. According to the manufacturer’s dosage sugges-
tions, all patients in each group were administered a total
dose of 100 mg of phospholipids/kg birth weight (4 mL/kg)
divided into four quarter-doses. Beractant was taken into
the disposable injectors with a large gauge needle (at least
20 G) without shaking. Following attachment of the in-
jectors to 5 French end-hole catheters premeasured ac-
cording to the lengths of endotracheal tubes of each baby,
at the discretion of the clinician, the endotracheal tube
108 A. Karadag et alwas suctioned before administering surfactant. The infant
was allowed to stabilize before proceeding with dosing. In
Group I, after injection of each quartile dose (1 mL/kg) of
surfactant in 2 seconds, the catheter was rapidly withdrawn
from the endotracheal tube, and the babies were manually
ventilated for 30 seconds at a rate of 60 breaths/min via a
hand bag with sufficient oxygen to prevent cyanosis. The
same process was repeated for each position. After the last
quarter dosing and 30 seconds of manual ventilation, the
infant was extubated if the need for FiO2 was < 40%; if it
was over, he/she was mechanically ventilated. Also in
Group II, a quarter dose of surfactant was administered
while the head of the baby was on the right in the same
position defined above, and 30 seconds of manual ventila-
tion was applied, keeping the position of the baby un-
changed. After the second quarter dosing in the same
position, the baby was ventilated for 30 seconds. The same
procedure was followed for the left position of the head.
Thirty seconds of ventilation was applied after the last
quarter dosing, and continuous positive airway pressure
(CPAP) or mechanical ventilation was chosen according to
the need for FiO2. In Group III, after each quarter dosing in
a neutral position, the catheter was withdrawn and the
baby was ventilated for 30 seconds. Following the last
quarter dosing, as in the previous groups, the baby was
ventilated for 30 seconds, and CPAP or a mechanical
ventilator was applied. Additional doses (up to 3 doses) of
beractant were given if the newborn required mechanical
ventilator support or if FiO2  0.40 was required to main-
tain the oxygen saturation at  86% by pulse oximeter, plus
radiological RDS Grade  3. The additional doses were
administered in accordance with the positions in each
group.
Details concerning patients’ sex, gestational age, birth
weight, Apgar scores, type of delivery, as well as maternal
risk factors including maternal age, prenatal steroid
administration, chorioamnionitis, multiple pregnancies,
and preeclampsia were obtained. In addition, data such as
total mechanical ventilation and CPAP duration, required
surfactant doses, lowest saturation levels, heart rate during
surfactant administration, FiO2 and saturation levels before
and after the initial surfactant applications, RDS grades in
chest X-ray, and total hospitalization duration for all infants
were recorded. The groups were also compared for the
following complications until 1 month after their discharge:
patent ductus arteriosus (PDA), pneumothorax, intraven-
tricular hemorrhage (IVH), chronic lung disease (CLD),
retinopathy of prematurity (ROP), necrotizing enterocolitis
(NEC), death within the first 3 days of life, death within the
first 28 days of life, and rehospitalization within 1 month
after discharge.
Recorded CLD was confirmed using the National Institute
of Health diagnostic criteria for CLD.12 Clinical findings of
systemic infection with positive blood culture helped to
diagnose neonatal sepsis. In addition, cranial ultrasonog-
raphy was used to detect IVH, and grading was carried out
using Papile’s classification.13 Patent ductus arteriosus
(PDA) was considered clinically significant if a defect was
confirmed by echocardiogram with ductal size > 2 mm and
a left atrial diameter/aortic root ratio of > 1.5 mm
together with left ventricular enlargement. NEC was also
among diagnosed problems; NEC was classified according toBell’s14 criteria. ROP was confirmed by following the in-
ternational classification.15
Only conventional ventilation was used in this study. The
ventilator strategies and initiating and weaning procedures
were standardized. The standard initiating settings for
mechanical ventilation were as follows: peak inspiratory
pressure (PIP) of 15e20 cmH2O, positive end expiratory
pressure (PEEP) of 4e6 cmH2O, flow rate 6e8 L/min,
ventilator rate 30e40/min, and an aspiratory/expiratory
ratio of 1:2. The weaning was started when the infant
required FiO2 < 0.30, and the patient was able to cope with
satisfactory blood gases at a flow rate of < 20/min and PIP
 15 cmH2O once clinically and radiologically stable.
Adescriptive analysiswas performed for demographic and
clinical characteristics of the patients. For nonparametric
values such as the lowest saturation rate during administra-
tion of surfactant and the saturation level before surfactant
application, we used the Kruskal-Wallis test. For the other
parametric values, one-way analysis of variance test was
used. Pearson’s Chi-square test was performed for the cat-
egorical variables. All statistical analyses were performed
using SPSS software, version 17.0 (SPSS Inc., Chicago, IL,
USA), and the statistical significance was set at p < 0.05.
3. Results
In this study, 132 preterm newborns were included from
January 2013 to February 2014 at four different centers in
Turkey. Seven of these infants were immediately excluded
from the study because of misdiagnosis or inappropriate
surfactant administration methods (Figure 4). Finally, a
total of 125 preterm newborns with RDS were included.
Groups I and II included 42 infants in each, whereas Group
III included 41 infants. The details concerning patients’
characteristics are shown in Table 1. There were no sig-
nificant differences among the three groups with regards to
gestational age, birth weight, sex, type of delivery, Apgar
scores, antenatal steroid administration, RDS grade, posi-
tive pressure ventilation requirement at delivery room,
maternal age, and some maternal risk factors.
Similarly, there were no notable differences among the
groups in terms of surfactant application-related issues and
ventilation support needs (Table 2). Any serious complica-
tions such as pneumothorax, need for resuscitation, or
perforation in the trachea or the esophagus in any of the
groups during the surfactant administration process were
recorded. Comparing the extubation success rates in the
first 72 hours of the operations, we did not observe any
significant difference (p Z 0.88).
The first 3 days and overall mortality rates were similar
in the three groups (Table 3). Other follow-up outcomes
including hospitalization duration, NEC, CLD, CLD-free
survival, ROP, Grade 3e4 IVH, PDA, sepsis, pneumothorax,
pulmonary hemorrhage and rehospitalization rates within
the 1st month after discharge were also similar in the three
groups (Table 3).
4. Discussion
Throughout our study, we found no significant differences
with regards to the administration of the beractant among
Figure 4 Flow diagram of the patients included in the present study.
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the two positions, and the neutral position in terms of
application, efficacy, and possible complications in the
early and late periods.
The main idea behind the four positions included in the
manufacturer’s instructions is to get the surfactant to as
many alveoli as possible. The four position administration
allows the fluid to come into contact with the upper and
lower quadrants of the lungs, and the right and left lobes.16
It is assumed that the gravity will help the surfactant to beTable 1 Demographic characteristics of the patients.
Group I
n Z 42
Gestational age (wk) 28.6  1.81
Birth weight (g) 1099  225
Male 24 (57.1)
Caesarean section 34 (81)
Apgar score at 1 min 4 (2e7)
Apgar score at 5 min 7 (5e9)
Antenatal steroid use 22 (52.4)
Number of surfactant administration 1.35  0.61
Maternal age (y) 27  5.1
Preeclampsia 11 (26.8)
PPV in delivery room 15 (35.7)
RDS grade 2.35  0.93
Data are presented as n (%), median (range), mean  SD.
PPV Z positive pressure ventilation; RDS Z respiratory distress syndredistributed between the two lungs after the instillation.
In other words, this method is intended to facilitate the
surfactant to access the various lobes of the lungs. More-
over, these were the positions validated during the clinical
trials for FDA approval of the drug. AbbVie (Chicago, IL,
USA), the manufacturing company or independent re-
searchers have not conducted any clinical trials to test
other positional permutations since then. Current clinical
recommendations on the positioning of infants during sur-
factant instillation of beractant vary according to theGroup II
n Z 42
Group III
n Z 41
p
28.5  1.73 28.1  1.68 0.27
1143  220 1068  158 0.51
23 (54.8) 18 (43.9) 0.43
34 (%81) 30 (73.2) 0.61
4 (2e8) 4 (2e7) 0.39
7 (5e9) 7 (5e9) 0.84
21 (50) 19 (46.3) 0.85
1.35  0.57 1.34  0.57 0.98
27.1  6.3 28.8  5.3 0.19
13 (31) 11 (26.8) 0.87
12 (28.6) 19 (46.3) 0.24
2.57  0.83 2.58  0.89 0.39
rome.
Table 2 Surfactant administration related primary outcomes.
Group I Group II Group III p
< 100/min pulse during surfactant administration 4 (9.5) 5 (11.9) 4 (9.8) 0.92
Minimum sPO2 during surfactant administration (%) 77.7  6.7 78.2  7.5 80.4  7.1 d
Endotracheal reflux of surfactant 4 5 5 0.72
FiO2 before surfactant administration 59  23 57  18 56  25 0.67
FiO2 after surfactant administration 50  13 49  14 46  12 0.30
FiO2 difference (before & after surfactant administration) 10.1  6.8 7.5  6.3 7.6  5.9 0.18
sPO2 before surfactant administration 86.9  4.3 87.7  4.7 88.7  4.4 d
sPO2 after surfactant administration 91.1  3.1 92.1  3.2 92.4  2.8 0.58
sPO2 difference (before & after surfactant administration) 3.7  2.9 4.3  3.1 4.8  3 0.55
FiO2 on the 3
rd day 43  16 42  14 44  16 0.97
sPO2 on the 3
rd day 92  2.8 92.5  2.8 93  2.9 0.35
Extubation success within 72 h 27 (64.3) 29 (69) 28 (68.3) 0.88
Total CPAP duration (h) 110  132 103  96 117  107 0.63
Total mechanical ventilation duration (h) 72.8  118.1 76.3  99.6 69.5  86.5 0.31
Data are presented as n, n (%) or mean  SD.
CPAP Z continuous positive airway pressure; FiO2 Z fraction of inspired oxygen; sPO2 Z saturation of peripheral oxygen.
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port other clinical practices, and the volume of published
material that compares the four positions with other posi-
tions is very small.
A study by Zola et al17, the sole study so far to compare
the suggested four positions with other positions in
newborn infants, relates the beractant administration ex-
periments in infants with RDS through a catheter inserted
into the endotracheal tube. In this research, infants were
positioned in accordance with three different approaches:
“in two positions along with the removal of the infant from
the ventilator;” “in two positions and without the removal
of the infant from the ventilator;” and in the manufacturer-
recommended four positions.17 The results of the study
showed no significant differences among the groups with
regards to the infant clinical outcomes (ventilation re-
quirements, oxygenation, mortality, and the incidence of
pulmonary air leaks) in the first 72 hours of life.17 Applying
the surfactant in the neutral position in a separate groupTable 3 Surfactant administration related secondary outcomes
Gro
Total hospitalization duration days 46.8
Total mortality 21.4
Mortality within the 1st 3 days 4.8
Necrotising enterocolitis 9.8
Chronic lung disease 14.3
CLD-free survival 69
ROP 10
Grade 3e4 IVH 4.8
PDA 14 (
Sepsis 9.5
Pneumothorax 10.4
Pulmonary hemorrhage 7.1
Rehospitalization within 1 month after the discharge 7.1
Data are presented as % or n (%).
CLD Z chronic lung disease; IVH Z intraventricular hemorrhage; PDAand administering the surfactant in four fractional doses in
each group constitute the most notable differences be-
tween the authors’ analysis and the present study. How-
ever, since there were no significant differences among the
groups after the application of the surfactant in the latter,
it is safe to assume that both studies support the effective
and accurate usage of the surfactant in other methods of
positioning other than the four position administration
recommended by the manufacturer.
It has been argued that surfactant application on
neonatal piglets in four different positions “improved the
outcome because of the rapid distribution of intra-
tracheally administered surfactant to the lungs”.16 Davis
et al16 used radio-scintiscanning to determine the initial
movement of a bovine surfactant labeled with Tc99m into
the lungs of piglets with RDS. The bovine surfactant was
instilled as a single intratracheal dose followed by distri-
butional assessments for 30 minutes.16 It was observed that
the surfactant was rapidly and symmetrically distributed to.
up I Group II Group III p
 23.2 44.2  18.1 55.1  25.4 0.09
26.2 22 0.85
4.8 4.9 1
9.8 9.8 0.99
16.7 17.1 0.93
64.3 63.4 0.84
7.1 7.3 0.90
2.4 0 0.62
33.3) 13 (31) 11 (26.8) 0.42
4.8 7.3 0.70
14.3 9.8 0.55
9.5 7.3 0.90
4.8 9.8
Z patent ductus arteriosus; ROP Z retinopathy of prematurity.
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concluded that the surfactant lowered surface tension in
proportion down to its interfacial concentration. At this
point, the addition of the surfactant to one region creates
surface tension gradients relative to other portions, and the
spreading surfactant is continually directed to the lung
periphery.16 We speculate that interfacial spreading effect
may facilitate the rapid delivery of the beractant into
aerated lungs regardless of the position of administration.
A study by Broadbent et al18 on rabbits with RDS showed
that positioning during surfactant application did not
actually affect the distribution of the compound in the
lungs and “that keeping the chest in the horizontal position
might result in most even distribution of the surfactant in
the two lungs”. Another study that compared surfactant
administration in a single dose with surfactant administra-
tion through slow tracheal infusion on rabbits showed that
bolus application provided more accurate results.19 A
similar study concentrated on the different effects of sur-
factant application in three groups of sheep with RDS that
were given surfactant in four positions with four boluses,
two lateral positions with two boluses, and a 30 minute
infusion. The study confirmed the surfactant distribution in
the lungs in the groups that underwent bolus surfactant
administration in two positions and in four positions without
any significant difference among the bolus groups.20 Taking
all these animal-based tests into consideration, one may
conclude that positioning in surfactant administration does
not really have an effect on the surfactant distribution in
the lungs while bolus applications are visibly more efficient
compared to the infusion of the compound. That is also why
the surfactant manufacturers, without any exceptions,
instruct administration of the surfactant in bolus place-
ments (all in a single dose, or the total dose in 2 or 4 ali-
quots) in several positions such as four position
administration (Survanta), two position administration
(Infasurf), or without any specific positioning (Curosurf).
The Fetus and Newborn Committee of the Canadian
Pediatric Society guideline concluded that there was no
evidence to support the practice of placing the infant in
multiple different positions during the administration of
surfactant.21 The American Academy of Pediatrics (AAP)
Committee on Fetus and Newborn has similarly concluded
that there is not sufficient evidence to recommend an
optimal number of fractional doses of surfactant or what
body position is best when surfactant is administered.22
However, health care professionals have tried other com-
putations of body positions over the years to find out which
works best for their individual units. In Turkey, there are
different approaches to positioning the infants during the
administration of Survanta, one of the two accessible sur-
factants in the country. The common practice in Turkey is
to place the surfactant intratracheally in two different
positions or in neutral position with four equal aliquots.
However, the present study, based on the data from four
different centers in the country, has clearly shown that
there are no significant differences among the three posi-
tioning approaches in beractant applications.
Surfactant administration procedures may be compli-
cated and require the supervision of clinicians experienced
in tracheal intubation, ventilator practices, and manage-
ment of preterm infants. The most commonly reportedcomplications include transient airway obstruction, brady-
cardia, oxygen desaturation, and pulmonary hemor-
rhage.22e24 Throughout the study, we observed bradycardia
(< 100 pulse/min) in approximately 10% of our patients
from all three groups with an 8e10% decline in their satu-
ration of peripheral oxygen (sPO2) levels, although we did
not need to apply chest compression or adrenalin upload in
any of these patients. Furthermore, we did not find any
relation between administering the beractant in different
positions and surfactant placement-related complications.
Surfactant application decreases mortality and
morbidity rates in RDS.25 It has also positive results in many
parameters like pneumothorax, pulmonary interstitial
emphysema, and hospitalization duration.3,22,26 Although
CLD frequency has unexpectedly increased compared to
the periods before surfactant administration, this increase
has opened the way for high levels of life expectancy in
younger infants, and so for more healthy infant discharges
from hospitals with CLD. As far as these results are con-
cerned, numerous comparative studies conducted with
different surfactants have come up with various re-
sults.6,8,27,28 Here, it is beneficial to keep in mind that
beractant administration, similar to other surfactant com-
pounds, reduces morbidity and mortality in infants with RDS
or premature infants. However, there is not enough evi-
dence with respect to the efficacy of administration
methods other than the ones offered by the manufacturers
on morbidity and mortality rates. Our study has shown no
differences among the various beractant administration
practices mentioned above with regards to mortality, me-
chanical ventilation and CPAP duration, hospitalization
duration, rehospitalization within 1 month after the
discharge, and prematurity- or RDS-related complications
like NEC, CLD, ROP, IVH, and pneumothorax.
In conclusion, our study found no significant differences
among the administration of the beractant in preterm in-
fants with RDS in four positions as recommended by the
manufacturer, two positions, and the neutral position in
terms of effectiveness and adverse effects. Therefore,
instead of relying solely on the manufacturer-instructed
four positions, administering the beractant in two positions
and in neutral position is equally reliable and safe, not to
mention easier and more practical.
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